12:00 AM
 | 
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Pomaglumetad methionil: Development discontinued

Eli Lilly discontinued development of pomaglumetad methionil after a futility analysis showed that the double-blind, international Phase III H8Y-MC-HBBN trial of the compound was "unlikely to be positive" on the primary endpoint of improving PANSS total score from baseline vs. placebo if enrolled to completion. Lilly said the decision was not based on any safety signals. The trial was designed to enroll about 1,100 patients with schizophrenia to receive placebo or twice-daily 10, 40...

Read the full 347 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >